Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Up 5.36%
As of Wednesday, October 21, Hemab Therapeutics Holdings, Inc.’s COAG share price has surged by 5.36%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Hemab Therapeutics Holdings, Inc. (COAG)
Hemab Therapeutics Holdings, Inc. COAG
$38.50
0.10
0.26%
October 28, 2026 4:00:00 PM
EST
Volume: 414,023
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Commentary & Analysis
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Down 5.20%
As of Friday, October 16, Hemab Therapeutics Holdings, Inc.’s COAG share price has dipped by 5.20%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Up 5.85%
As of Thursday, October 15, Hemab Therapeutics Holdings, Inc.’s COAG share price has surged by 5.85%, which has investors questioning if this is right time to sell.Michael Rose
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Up 11.09%
As of Thursday, October 15, Hemab Therapeutics Holdings, Inc.’s COAG share price has surged by 11.09%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Hemab Therapeutics Holdings, Inc.’s (COAG) Stock Is Up 5.78%
As of Friday, October 09, Hemab Therapeutics Holdings, Inc.’s COAG share price has surged by 5.78%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | COAG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,790.5 | $227.8 | 53% |
|
| Shares Out (Mil) | 30.1 | 53.4 | 37% |
|
| Institutional Ownership | 99.4% | 92.9% | 88% |
|
| Float (Mil) | 20.3 | 41.2 | 29% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 338 | 513 | 53% |
|
| Price Change (52-week) |
na | 47.3% | na |
|
| Growth | COAG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.515) | ($3.109) | ($2.547) | |
| Month Ago EPS | ($0.510) | ($3.100) | ($2.538) | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | ($0.487) | ($3.063) | ($2.513) | |
| Year/Year Chg | (35.8%) | (95.4%) | (95.4%) | |
| Financials | COAG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($83) | ($44) | 13% |
|
| EPS (TTM) | ($10.055) | ($1.500) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($77) | ($34) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $137 | $2 | 80% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | $1,317 | $177 | 44% |
|
| Valuation | COAG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.94 | 2.22 | 75% |
|
| P/E | na | 20.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | COAG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (75.3%) | na |
|
| ROA | (35.6%) | (47.1%) | 15% |
|
| ROE | (36.6%) | (53.3%) | 18% |
|
| Liabilities to Assets | 2.9% | 29.3% | 1% |
|
| F-Score | 1 | 2 | na |
|
Hemab Therapeutics Holdings, Inc. did not pass any screens on 10/27/2026.
